🏷

Classifications

Harrison's Part

Channelopathy

🔗

Mappings

MONDO

MONDO:0017385 malignant migrating partial seizures of infancy

MONDO:0017385 (malignant migrating partial seizures of infancy) is the current MONDO concept for EIMFS; it replaces the now-obsolete MONDO:0100025. The preferred_term keeps the modern ILAE label (epilepsy of infancy with migrating focal seizures).

NCIT

NCIT:C125387 Migrating Partial Seizures in Infancy

MONDO:0017385 carries NCIT:C125387 as a cross-reference and takes its definition from that NCIT concept; the NCIT label is the older "migrating partial seizures" designation for the same syndrome.

ICD-10-CM

ICD10CM:G93.45 Developmental and epileptic encephalopathy

ICD-10-CM has no EIMFS-specific rubric. G93.45 is the ICD-10-CM developmental and epileptic encephalopathy code, and EIMFS is an ILAE developmental and epileptic encephalopathy syndrome; recorded as a broadMatch because the code covers every DEE syndrome.

ICD-11 Foundation

icd11f:1727727812 Epilepsy of infancy with migrating focal seizures

The ICD-11 Foundation entity label is identical to the modern ILAE syndrome name this entry uses as its preferred_term, so it names the same syndrome as MONDO:0017385 under its current designation.

NCIT

NCIT:C125387 Migrating Partial Seizures in Infancy

MONDO:0017385 carries NCIT:C125387 as a cross-reference and takes its definition from that NCIT concept; the NCIT label is the older "migrating partial seizures" designation for the same syndrome.

👪

Inheritance

1

Autosomal dominant (de novo) HP:0000006

KCNT1-related EIMFS is inherited in an autosomal dominant manner; nearly all affected individuals have the disorder as the result of a de novo KCNT1 pathogenic variant.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"KCNT1-related epilepsy is inherited in an autosomal dominant manner"

GeneReviews states KCNT1-related epilepsy is autosomal dominant, with EIMFS typically arising de novo.

?

Discussions and Knowledge Gaps

3

KCNT1 variants in EIMFS increase a potassium current, which in isolation is hyperpolarizing and would be expected to reduce excitability - yet the result is severe, near-continuous seizures. By what circuit mechanism does a gain-of-function potassium channel produce network hyperexcitability, and how central is the proposed preferential effect on inhibitory interneurons?

KNOWLEDGE GAP OPEN eimfs-gof-hyperexcitability-paradox

Attached to

pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction pathophysiology#Increased Slack Sodium-Activated Potassium Current

Resolving the gain-of-function paradox is essential for rational therapy: if the seizures arise chiefly from interneuron dysfunction, the therapeutic logic (and the interpretation of channel blockers) differs from a model in which principal-neuron firing is the driver. The interneuron hypothesis is plausible but not firmly established in human cortex.

Proposed experiments

Cell-type-resolved circuit study of KCNT1 gain of function

eimfs-celltype-circuit

Use cell-type-specific expression of EIMFS KCNT1 variants in excitatory versus inhibitory neurons (in iPSC-derived human neurons and animal models) with circuit-level recording to determine how the enhanced current translates into network hyperexcitability.

Readouts

Effect of KCNT1 gain of function by neuron type on network excitability

pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction

Would support

pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction

Quinidine blocks gain-of-function KCNT1 channels in vitro, motivating its use as a precision therapy, yet clinical benefit in EIMFS is inconsistent (around 45% of patients). Why does the in vitro channel block translate so variably to seizure control - is it variant-specific pharmacology, CNS penetration, QT-limited dosing, or timing relative to established encephalopathy?

HUMAN MODEL MISMATCH OPEN eimfs-quinidine-variable-response

Attached to

pathophysiology#Increased Slack Sodium-Activated Potassium Current

The mismatch between reliable in vitro block and variable clinical response is the central obstacle to KCNT1 precision therapy. Evidence for target engagement exists in cell models, but its translational validity for seizure control in patients is uncertain, so predicting responders remains unsolved.

Proposed experiments

Variant-stratified quinidine response study

eimfs-quinidine-responder

Correlate quinidine clinical response with KCNT1 variant, in vitro block potency, achieved CSF/plasma levels, QT-limited dosing, and age at treatment across a multicenter EIMFS cohort to identify determinants of response.

Readouts

Seizure response versus variant, drug level, and timing

pathophysiology#Migrating Focal Seizure Generation

Decision criterion

Identification of reproducible responder predictors would support variant-stratified quinidine use.

Would support

pathophysiology#Increased Slack Sodium-Activated Potassium Current

Gain-of-function KCNT1 variants cause a spectrum from severe EIMFS to the much milder autosomal dominant sleep-related hypermotor epilepsy. What determines whether the same channel defect produces devastating migrating seizures or a relatively mild focal epilepsy - variant location, degree of gain of function, mosaicism, or modifiers?

KNOWLEDGE GAP OPEN eimfs-kcnt1-genotype-phenotype

Attached to

pathophysiology#KCNT1 Gain-of-Function Mutation

Understanding what sets phenotypic severity from a shared gene would improve prognostic counseling and might reveal modifiable factors, but the genotype-phenotype relationship for KCNT1 is only partially mapped.

Proposed experiments

KCNT1 genotype-severity mapping

eimfs-kcnt1-genotype-severity

Relate the degree of channel gain of function (and variant location and mosaic fraction) to clinical severity across the KCNT1 phenotypic spectrum using functional assays and deep phenotyping.

Readouts

Gain-of-function magnitude versus clinical severity

pathophysiology#KCNT1 Gain-of-Function Mutation

Would support

pathophysiology#KCNT1 Gain-of-Function Mutation

⚙

Pathophysiology

6

KCNT1 Gain-of-Function Mutation

A gain-of-function variant in KCNT1, which encodes the sodium-activated potassium channel Slack (KNa1.1), is the most common cause of EIMFS. This node captures the single concept of the initiating channel lesion.

KCNT1 hgnc:18865

intracellular sodium-activated potassium channel activity GO:0005228 ↑ INCREASED

Downstream

Increased Slack Sodium-Activated Potassium Current The gain-of-function variant increases the Slack (KNa) potassium current.

Show evidence (1 reference)

PMID:23086397 SUPPORT Human Clinical

"We performed exome sequencing in three probands with MMPSI and identified de novo gain-of-function mutations affecting the C-terminal domain of the KCNT1 potassium channel"

The seminal study identifying de novo gain-of-function KCNT1 mutations as the cause of migrating focal seizures of infancy.

Increased Slack Sodium-Activated Potassium Current

The gain-of-function variant markedly increases the amplitude of the sodium-activated potassium (KNa) current carried by the Slack channel. This node captures the single concept of the enhanced potassium conductance and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Potassium ion transmembrane transport GO:0071805 ↑ INCREASED

Downstream

Disrupted Neuronal Firing and Interneuron Dysfunction The enhanced potassium current alters neuronal firing patterns, including in inhibitory interneurons.

Show evidence (1 reference)

PMID:23086397 SUPPORT In Vitro

"Functional studies showed that the mutations led to constitutive activation of the channel"

Functional studies showed the KCNT1 mutations constitutively activate the Slack channel, increasing the potassium current.

Disrupted Neuronal Firing and Interneuron Dysfunction

The enhanced Slack current alters the firing of cortical neurons; a leading interpretation is that its effect on inhibitory interneurons paradoxically disinhibits the network. This node captures the single concept of the altered firing/inhibition.

GABAergic neuron CL:0000617

Downstream

Multifocal Cortical Hyperexcitability Disrupted firing and impaired inhibition produce multifocal cortical hyperexcitability.

Show evidence (1 reference)

PMID:35346832 SUPPORT DIRECT PRIMARY RESULT Model Organism

"parvalbumin-expressing (PV+) interneurons failed to fire repetitively with large amplitude current injections and were more prone to depolarization block"

Patch-clamp recordings in a Kcnt1 gain-of-function knock-in mouse show the altered firing and impaired inhibitory output this node describes, located specifically in parvalbumin-positive interneurons.

Multifocal Cortical Hyperexcitability

Multiple cortical regions in both hemispheres become independently hyperexcitable and epileptogenic. This node captures the single concept of multifocal network hyperexcitability and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Migrating Focal Seizure Generation Independent multifocal hyperexcitability generates seizures that migrate across cortical regions.

Show evidence (1 reference)

PMID:23086397 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"EEG disclosed multifocal paroxysmal abnormalities affecting alternatively both hemispheres"

EEG in the MMPSI cohort records independently epileptogenic regions in both hemispheres, the clinical expression of the multifocal hyperexcitability this node describes.

Migrating Focal Seizure Generation

Focal seizures arise independently in both hemispheres and migrate from one cortical region to another, often nearly continuously and with status epilepticus. This node captures the single concept of the characteristic seizure pattern and conforms to the shared epilepsy final common pathway.

Neuron CL:0000540

Downstream

Severe Developmental and Epileptic Encephalopathy The relentless seizure burden and underlying channel dysfunction drive severe developmental impairment.

Migrating Focal Seizures The generated seizure pattern is observed clinically as migrating focal seizures, the defining feature of the syndrome.

Refractory Status Epilepticus Because the migrating seizures are near-continuous, they frequently evolve into refractory status epilepticus.

Autonomic Manifestations (Apnea, Cyanosis) Ictal spread to autonomic networks produces the common perioral cyanosis, flushing, and apnea accompanying the seizures.

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"EIMFS is characterized by seizures, typically focal and asynchronous, beginning in the first six months of life with associated developmental plateau or regression"

GeneReviews describes the defining seizure pattern of EIMFS as focal and asynchronous — that is, arising independently across cortical regions — which is the clinical expression of this node.

Severe Developmental and Epileptic Encephalopathy

Profound global developmental impairment accompanies and is aggravated by the relentless seizures, with acquired microcephaly and movement abnormalities common. This node captures the single concept of the encephalopathic outcome.

Neuron CL:0000540

Downstream

Epileptic Encephalopathy The relentless epileptic activity superimposed on the channel defect is the epileptic encephalopathy itself.

Severe Developmental Delay The encephalopathy is expressed clinically as profound global developmental delay.

Developmental Regression Milestone plateau or regression accompanies seizure onset as the encephalopathy establishes itself.

Acquired Microcephaly Head growth falls off postnatally, typically by age 12 months; the intermediates linking the encephalopathy to arrested brain growth are not established.

Axial Hypotonia Axial hypotonia is part of the neurologic picture accompanying the encephalopathy, through intermediates that have not been resolved.

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"Additional neurologic features include hypotonia, microcephaly developing by age 12 months, strabismus, profound developmental delay, and additional movement disorders"

GeneReviews records the encephalopathic outcome of this node — profound developmental delay with postnatally acquired microcephaly, hypotonia and movement abnormalities.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Head and Neck 1

Acquired Microcephaly Secondary microcephaly HP:0005484

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"Additional neurologic features include hypotonia, microcephaly developing by age 12 months"

GeneReviews lists postnatally-developing microcephaly as a neurologic feature.

Musculoskeletal 1

Axial Hypotonia HP:0008936

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"Additional neurologic features include hypotonia, microcephaly developing by age 12 months"

GeneReviews lists hypotonia among the neurologic features.

Nervous System 5

Migrating Focal Seizures HP:0032786

Onset: INFANTILE

Show evidence (1 reference)

PMID:23086397 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"video-EEG recordings showed in all patients the specific migrating feature"

Every patient in the MMPSI cohort showed the migrating seizure pattern on video-EEG, documenting this phenotype.

Refractory Status Epilepticus HP:0002133

Show evidence (1 reference)

PMID:30234941 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Seizures are intractable to multiple anticonvulsants and progress to become nearly continuous by age six to nine months"

GeneReviews documents drug-resistant seizures becoming nearly continuous in the first year, the near-status-epilepticus phenotype recorded here.

Epileptic Encephalopathy HP:0200134

Show evidence (1 reference)

PMID:23086397 SUPPORT DIRECT BACKGROUND Human Clinical

"Malignant migrating partial seizures of infancy (MMPSI) is a rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay"

The syndrome is classified as an epileptic encephalopathy combining drug-resistant seizures with developmental impairment.

Severe Developmental Delay Severe global developmental delay HP:0011344

Show evidence (1 reference)

PMID:30234941 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"strabismus, profound developmental delay, and additional movement disorders"

GeneReviews lists profound developmental delay among the neurologic features of KCNT1-related epilepsy.

Developmental Regression HP:0002376

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"beginning in the first six months of life with associated developmental plateau or regression"

GeneReviews documents developmental plateau or regression accompanying EIMFS seizure onset.

Respiratory 1

Autonomic Manifestations (Apnea, Cyanosis) HP:0002104

Show evidence (1 reference)

PMID:30234941 SUPPORT Human Clinical

"Autonomic manifestations (e.g., perioral cyanosis, flushing, apnea) are common"

GeneReviews documents common autonomic manifestations including apnea and perioral cyanosis.

🧬

Genetic Associations

1

KCNT1

Gene: KCNT1 hgnc:18865 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (1 reference)

PMID:23086397 SUPPORT Human Clinical

"in total identifying mutations in 6 out of 12 unrelated affected individuals"

KCNT1 mutations were found in half of an MMPSI cohort, establishing it as the major causative gene.

💊

Medical Actions

4

Quinidine (KCNT1 Blocker)

Action: Pharmacotherapy NCIT:C15986

Agent: quinidine CHEBI:28593

Platform: Small molecule

Quinidine, a partial blocker of the Slack (KCNT1) channel, has been used as a precision therapy that targets the gain-of-function mechanism. In a systematic review of KCNT1-related epilepsy it benefited a subset of EIMFS patients (about 45%), with variable responses and required cardiac QT monitoring.

Mechanism Target:

INHIBITS Increased Slack Sodium-Activated Potassium Current — Quinidine partially blocks the gain-of-function Slack potassium current.

Show evidence (1 reference)

PMID:24591078 SUPPORT DIRECT PRIMARY RESULT In Vitro

"exposure to quinidine significantly reduces this gain of function for all mutations studied"

Two-electrode voltage clamp of human KCNT1 variants, including the EIMFS-associated ones, shows quinidine reduces the gain of function, which is the mechanism this link asserts.

Show evidence (1 reference)

PMID:39093319 SUPPORT Human Clinical

"QUIN resulted in benefit in 44.6% (25/56)"

In a systematic review, quinidine benefited about 45% of EIMFS patients, supporting it as a partially effective precision therapy.

Ketogenic Diet

Action: dietary intervention Ontology label: Dietary Intervention NCIT:C15447

The ketogenic diet is a useful option in KCNT1-related epilepsy and, in a systematic review, benefited the largest fraction of EIMFS patients among the therapies compared.

Show evidence (1 reference)

PMID:39093319 SUPPORT Human Clinical

"KD resulted in benefit in 62.5% (25/40)"

The ketogenic diet benefited 62.5% of EIMFS patients in the systematic review, the highest response among compared therapies.

Cannabidiol

Action: Pharmacotherapy NCIT:C15986

Agent: cannabidiol CHEBI:69478

Platform: Small molecule

Cannabidiol has been trialed in KCNT1-related epilepsy and benefited about half of the EIMFS patients in a systematic review.

Show evidence (1 reference)

PMID:39093319 SUPPORT Human Clinical

"all types of CBD resulted in benefit in 50% (6/12)"

In a systematic review, cannabidiol benefited 50% of EIMFS patients in whom it was tried.

Antiseizure Medication

Action: Pharmacotherapy NCIT:C15986

Broad-spectrum antiseizure medications are used, but seizures are typically highly drug-resistant and conventional agents are only rarely beneficial.

Show evidence (1 reference)

PMID:39093319 SUPPORT Human Clinical

"conventional ASM are rarely reported as beneficial (in 5%-25% of patients)"

Conventional antiseizure medications are only rarely beneficial in KCNT1-related epilepsy, underscoring the drug-resistance.

📊

Prevalence

1

Worldwide

Unknown Ultra Rare

EIMFS is an ultra-rare developmental and epileptic encephalopathy; a precise population prevalence is not established. KCNT1 gain-of-function variants account for roughly 40-50% of cases.

Show evidence (1 reference)

PMID:23086397 SUPPORT INDIRECT BACKGROUND Human Clinical

"To date, approximately 80 MMPSI patients have been reported with males and females being equally affected"

A cumulative literature total of roughly 80 reported patients places the syndrome in the ultra-rare band. Graded INDIRECT because a case count is not a population prevalence measurement.

📊

Related Datasets

1

Therapeutic Potential of ASO-Mediated KCNT1 Knockdown in KCNT1 Epileptic Encephalopathy geo:GSE297948

KCNT1-related epileptic encephalopathy, including Epilepsy of Infancy with Migrating Focal Seizures (EIMFS), is a severe neurodevelopmental disorder associated with refractory seizures, profound neurologic impairment, and premature death. It is caused by de novo genetic variants in KCNT1 which alter the function of Slack, an evolutionarily conserved sodium-gated potassium channel that modulates neuronal firing patterns and excitability. Pathogenic KCNT1 variants lead to overactive Slack channels, boosting total neuronal potassium currents by up to 40%, driving cortical hyperexcitability and causing seizures.

human BULK RNA SEQ n=12

PMID:41981306

Identified by GEO DataSets index search for Epilepsy of Infancy with Migrating Focal Seizures (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

{ }

Source YAML

click to show

name: Epilepsy of Infancy with Migrating Focal Seizures
creation_date: "2026-07-18T00:00:00Z"
category: Genetic
description: >-
  Epilepsy of infancy with migrating focal seizures (EIMFS; formerly malignant
  migrating partial seizures of infancy) is a severe developmental and epileptic
  encephalopathy beginning in the first months of life. It is defined by nearly
  continuous, drug-resistant focal seizures that arise independently in both
  hemispheres and migrate from one cortical region to another on EEG, together
  with profound developmental impairment. The most common cause is a
  gain-of-function variant in KCNT1, which encodes the sodium-activated
  potassium channel Slack (KNa1.1); the increased potassium current disturbs the
  excitability of cortical networks. Prognosis is poor, and standard antiseizure
  medications are largely ineffective; the KCNT1 blocker quinidine has been
  tried as a precision therapy with variable benefit, and the ketogenic diet
  helps a substantial subset.
parents:
- Epilepsy
- Neurological Disease
synonyms:
- EIMFS
- Malignant migrating partial seizures of infancy
- MMPSI
- MMPEI
disease_term:
  preferred_term: epilepsy of infancy with migrating focal seizures
  term:
    id: MONDO:0017385
    label: malignant migrating partial seizures of infancy
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:G93.45
      label: Developmental and epileptic encephalopathy
    mapping_predicate: skos:broadMatch
    mapping_source: manual curation
    mapping_justification: >-
      ICD-10-CM has no EIMFS-specific rubric. G93.45 is the ICD-10-CM
      developmental and epileptic encephalopathy code, and EIMFS is an ILAE
      developmental and epileptic encephalopathy syndrome; recorded as a
      broadMatch because the code covers every DEE syndrome.
  icd11f_mappings:
  - term:
      id: icd11f:1727727812
      label: Epilepsy of infancy with migrating focal seizures
    mapping_predicate: skos:exactMatch
    mapping_source: manual curation
    mapping_justification: >-
      The ICD-11 Foundation entity label is identical to the modern ILAE
      syndrome name this entry uses as its preferred_term, so it names the same
      syndrome as MONDO:0017385 under its current designation.
  mondo_mappings:
  - term:
      id: MONDO:0017385
      label: malignant migrating partial seizures of infancy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0017385 (malignant migrating partial seizures of infancy) is the
      current MONDO concept for EIMFS; it replaces the now-obsolete
      MONDO:0100025. The preferred_term keeps the modern ILAE label (epilepsy of
      infancy with migrating focal seizures).
  ncit_mappings:
  - term:
      id: NCIT:C125387
      label: Migrating Partial Seizures in Infancy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO:0017385
    mapping_justification: >-
      MONDO:0017385 carries NCIT:C125387 as a cross-reference and takes its
      definition from that NCIT concept; the NCIT label is the older
      "migrating partial seizures" designation for the same syndrome.
    consistency:
    - reference: MONDO:0017385
      consistent: CONSISTENT
      notes: "xref: NCIT:C125387"
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Malignant migrating partial seizures of infancy (MMPSI) is a rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay"
      explanation: >-
        The syndrome is defined as an epileptic encephalopathy of infancy, an
        epilepsy whose clinical home in Harrison's is the neurologic Part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis of KCNT1-related epilepsy is established in a proband with intractable epilepsy and a heterozygous pathogenic variant in KCNT1 identified by molecular genetic testing"
      explanation: >-
        Diagnosis rests on identifying a heterozygous pathogenic KCNT1 variant,
        so EIMFS is also a Mendelian single-gene disorder and takes the
        genetics Part alongside the neurologic one.
  channelopathy_category:
    classification_value: neurological channelopathy
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "identified de novo gain-of-function mutations affecting the C-terminal domain of the KCNT1 potassium channel"
      explanation: >-
        The causative lesion is a gain-of-function variant of the KCNT1
        (Slack/KNa1.1) potassium channel, and the resulting disease is a
        cortical epilepsy, which is what makes this a neurological
        channelopathy rather than a cardiac or muscle one.
references:
- reference: PMID:30234941
  title: "KCNT1-Related Epilepsy"
  tags:
  - GeneReviews
inheritance:
- name: Autosomal dominant (de novo)
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    KCNT1-related EIMFS is inherited in an autosomal dominant manner; nearly all
    affected individuals have the disorder as the result of a de novo KCNT1
    pathogenic variant.
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KCNT1-related epilepsy is inherited in an autosomal dominant manner"
    explanation: >-
      GeneReviews states KCNT1-related epilepsy is autosomal dominant, with EIMFS
      typically arising de novo.
pathophysiology:
- name: KCNT1 Gain-of-Function Mutation
  description: >-
    A gain-of-function variant in KCNT1, which encodes the sodium-activated
    potassium channel Slack (KNa1.1), is the most common cause of EIMFS. This
    node captures the single concept of the initiating channel lesion.
  role: trigger
  gene:
    preferred_term: KCNT1
    term:
      id: hgnc:18865
      label: KCNT1
  molecular_functions:
  - preferred_term: intracellular sodium-activated potassium channel activity
    term:
      id: GO:0005228
      label: intracellular sodium-activated potassium channel activity
    modifier: INCREASED
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We performed exome sequencing in three probands with MMPSI and identified de novo gain-of-function mutations affecting the C-terminal domain of the KCNT1 potassium channel"
    explanation: >-
      The seminal study identifying de novo gain-of-function KCNT1 mutations as
      the cause of migrating focal seizures of infancy.
  downstream:
  - target: Increased Slack Sodium-Activated Potassium Current
    causal_link_type: DIRECT
    description: >-
      The gain-of-function variant increases the Slack (KNa) potassium current.
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "These findings demonstrate that both mutant channels are constitutively activated, mimicking and occluding the effects of PKC activation"
      explanation: >-
        Expressing the patient KCNT1 variants in oocytes showed the channels are
        constitutively activated, which is the step from the variant to the
        enhanced current this edge asserts.
- name: Increased Slack Sodium-Activated Potassium Current
  description: >-
    The gain-of-function variant markedly increases the amplitude of the
    sodium-activated potassium (KNa) current carried by the Slack channel. This
    node captures the single concept of the enhanced potassium conductance and
    conforms to the shared epilepsy final common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Potassium ion transmembrane transport
    term:
      id: GO:0071805
      label: potassium ion transmembrane transport
    modifier: INCREASED
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional studies showed that the mutations led to constitutive activation of the channel"
    explanation: >-
      Functional studies showed the KCNT1 mutations constitutively activate the
      Slack channel, increasing the potassium current.
  downstream:
  - target: Disrupted Neuronal Firing and Interneuron Dysfunction
    causal_link_type: DIRECT
    description: >-
      The enhanced potassium current alters neuronal firing patterns, including
      in inhibitory interneurons.
    evidence:
    - reference: PMID:35346832
      reference_title: "K(Na)1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "these results suggest that KNa1.1 gain-of-function dampens interneuron excitability to a greater extent than it impacts pyramidal neuron excitability"
      explanation: >-
        In a Kcnt1 gain-of-function knock-in mouse the enhanced KNa current
        translates into blunted interneuron firing, which is the step this edge
        asserts.
- name: Disrupted Neuronal Firing and Interneuron Dysfunction
  description: >-
    The enhanced Slack current alters the firing of cortical neurons; a leading
    interpretation is that its effect on inhibitory interneurons paradoxically
    disinhibits the network. This node captures the single concept of the
    altered firing/inhibition.
  role: mediator
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  evidence:
  - reference: PMID:35346832
    reference_title: "K(Na)1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: "parvalbumin-expressing (PV+) interneurons failed to fire repetitively with large amplitude current injections and were more prone to depolarization block"
    explanation: >-
      Patch-clamp recordings in a Kcnt1 gain-of-function knock-in mouse show the
      altered firing and impaired inhibitory output this node describes, located
      specifically in parvalbumin-positive interneurons.
  downstream:
  - target: Multifocal Cortical Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Disrupted firing and impaired inhibition produce multifocal cortical
      hyperexcitability.
    evidence:
    - reference: PMID:35346832
      reference_title: "K(Na)1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "we hypothesize that decreasing their maximum achievable firing rate leads to a circuit-wide reduction in inhibitory tone, and can thus be considered proconvulsant"
      explanation: >-
        The authors state the inference this edge encodes: blunted interneuron
        firing reduces inhibitory tone across the circuit and is proconvulsant.
        Graded INDIRECT because the circuit-level step is inferred from the
        cellular recordings rather than measured directly.
- name: Multifocal Cortical Hyperexcitability
  description: >-
    Multiple cortical regions in both hemispheres become independently
    hyperexcitable and epileptogenic. This node captures the single concept of
    multifocal network hyperexcitability and conforms to the shared epilepsy
    final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "EEG disclosed multifocal paroxysmal abnormalities affecting alternatively both hemispheres"
    explanation: >-
      EEG in the MMPSI cohort records independently epileptogenic regions in
      both hemispheres, the clinical expression of the multifocal
      hyperexcitability this node describes.
  downstream:
  - target: Migrating Focal Seizure Generation
    causal_link_type: DIRECT
    description: >-
      Independent multifocal hyperexcitability generates seizures that migrate
      across cortical regions.
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "video-EEG recordings showed in all patients the specific migrating feature"
      explanation: >-
        The same cohort whose EEG shows multifocal abnormalities in both
        hemispheres also shows the migrating seizure pattern, linking the
        multifocal hyperexcitability to the seizures it generates.
- name: Migrating Focal Seizure Generation
  description: >-
    Focal seizures arise independently in both hemispheres and migrate from one
    cortical region to another, often nearly continuously and with status
    epilepticus. This node captures the single concept of the characteristic
    seizure pattern and conforms to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EIMFS is characterized by seizures, typically focal and asynchronous, beginning in the first six months of life with associated developmental plateau or regression"
    explanation: >-
      GeneReviews describes the defining seizure pattern of EIMFS as focal and
      asynchronous — that is, arising independently across cortical regions —
      which is the clinical expression of this node.
  downstream:
  - target: Severe Developmental and Epileptic Encephalopathy
    causal_link_type: DIRECT
    description: >-
      The relentless seizure burden and underlying channel dysfunction drive
      severe developmental impairment.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "beginning in the first six months of life with associated developmental plateau or regression"
      explanation: >-
        GeneReviews couples seizure onset with developmental plateau or
        regression, which is the encephalopathic outcome this edge asserts.
  - target: Migrating Focal Seizures
    causal_link_type: DIRECT
    description: >-
      The generated seizure pattern is observed clinically as migrating focal
      seizures, the defining feature of the syndrome.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "EIMFS is characterized by seizures, typically focal and asynchronous"
      explanation: >-
        The generated pattern is observed clinically as focal, asynchronous
        seizures, the phenotype this edge points at.
  - target: Refractory Status Epilepticus
    causal_link_type: DIRECT
    description: >-
      Because the migrating seizures are near-continuous, they frequently
      evolve into refractory status epilepticus.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Seizures are intractable to multiple anticonvulsants and progress to become nearly continuous by age six to nine months"
      explanation: >-
        GeneReviews records the progression from migrating focal seizures to a
        nearly continuous, drug-resistant seizure state, which is the
        near-status-epilepticus outcome this edge asserts.
  - target: Autonomic Manifestations (Apnea, Cyanosis)
    causal_link_type: DIRECT
    description: >-
      Ictal spread to autonomic networks produces the common perioral cyanosis,
      flushing, and apnea accompanying the seizures.
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "All patients presented polymorphous and focal motor seizures at onset with an autonomic components including cyanosis or bradycardia in 4"
      explanation: >-
        In the MMPSI cohort the autonomic features are reported as a component
        of the seizures themselves, which is the ictal origin this edge
        asserts.
- name: Severe Developmental and Epileptic Encephalopathy
  description: >-
    Profound global developmental impairment accompanies and is aggravated by
    the relentless seizures, with acquired microcephaly and movement
    abnormalities common. This node captures the single concept of the
    encephalopathic outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional neurologic features include hypotonia, microcephaly developing by age 12 months, strabismus, profound developmental delay, and additional movement disorders"
    explanation: >-
      GeneReviews records the encephalopathic outcome of this node — profound
      developmental delay with postnatally acquired microcephaly, hypotonia and
      movement abnormalities.
  downstream:
  - target: Epileptic Encephalopathy
    causal_link_type: DIRECT
    description: >-
      The relentless epileptic activity superimposed on the channel defect is
      the epileptic encephalopathy itself.
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "Malignant migrating partial seizures of infancy (MMPSI) is a rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay"
      explanation: >-
        The syndrome is defined as an epileptic encephalopathy combining
        drug-resistant seizures with developmental impairment, which is the
        identity this edge asserts.
  - target: Severe Developmental Delay
    causal_link_type: DIRECT
    description: >-
      The encephalopathy is expressed clinically as profound global
      developmental delay.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "strabismus, profound developmental delay, and additional movement disorders"
      explanation: >-
        GeneReviews records profound developmental delay as the clinical
        expression of the encephalopathy this edge originates from.
  - target: Developmental Regression
    causal_link_type: DIRECT
    description: >-
      Milestone plateau or regression accompanies seizure onset as the
      encephalopathy establishes itself.
    evidence:
    - reference: PMID:23086397
      reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "characterized by polymorphous focal seizures and arrest of psychomotor development in the first 6 months of life"
      explanation: >-
        Arrest of psychomotor development accompanying seizure onset is the
        regression this edge asserts. Quoted from the paper's introduction,
        where it restates the established clinical description of the syndrome.
  - target: Acquired Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Head growth falls off postnatally, typically by age 12 months; the
      intermediates linking the encephalopathy to arrested brain growth are not
      established.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "microcephaly developing by age 12 months"
      explanation: >-
        Microcephaly is recorded as developing postnatally, consistent with it
        following the established encephalopathy. Graded INDIRECT because the
        source reports the association without establishing the causal
        intermediates.
  - target: Axial Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Axial hypotonia is part of the neurologic picture accompanying the
      encephalopathy, through intermediates that have not been resolved.
    evidence:
    - reference: PMID:30234941
      reference_title: "KCNT1-Related Epilepsy."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Additional neurologic features include hypotonia"
      explanation: >-
        Hypotonia is listed among the neurologic features accompanying the
        encephalopathy. Graded INDIRECT because co-occurrence is reported
        without the mechanistic intermediates.
phenotypes:
- name: Migrating Focal Seizures
  description: >-
    Focal seizures that arise independently in both hemispheres and migrate
    across cortical regions are the defining feature.
  phenotype_term:
    preferred_term: Migrating focal seizure
    term:
      id: HP:0032786
      label: Migrating focal seizure
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "video-EEG recordings showed in all patients the specific migrating feature"
    explanation: >-
      Every patient in the MMPSI cohort showed the migrating seizure pattern on
      video-EEG, documenting this phenotype.
- name: Refractory Status Epilepticus
  description: >-
    Seizures are frequently prolonged, near-continuous, and evolve into status
    epilepticus.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Seizures are intractable to multiple anticonvulsants and progress to become nearly continuous by age six to nine months"
    explanation: >-
      GeneReviews documents drug-resistant seizures becoming nearly continuous
      in the first year, the near-status-epilepticus phenotype recorded here.
- name: Epileptic Encephalopathy
  description: >-
    The relentless epileptic activity contributes to a severe encephalopathy.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Malignant migrating partial seizures of infancy (MMPSI) is a rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay"
    explanation: >-
      The syndrome is classified as an epileptic encephalopathy combining
      drug-resistant seizures with developmental impairment.
- name: Severe Developmental Delay
  description: >-
    Profound global developmental delay with arrest or regression of milestones
    is characteristic.
  phenotype_term:
    preferred_term: Severe global developmental delay
    term:
      id: HP:0011344
      label: Severe global developmental delay
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "strabismus, profound developmental delay, and additional movement disorders"
    explanation: >-
      GeneReviews lists profound developmental delay among the neurologic
      features of KCNT1-related epilepsy.
- name: Developmental Regression
  description: >-
    Seizure onset is accompanied by a developmental plateau or regression.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "beginning in the first six months of life with associated developmental plateau or regression"
    explanation: >-
      GeneReviews documents developmental plateau or regression accompanying
      EIMFS seizure onset.
- name: Acquired Microcephaly
  description: >-
    Microcephaly develops postnatally, typically by age 12 months.
  phenotype_term:
    preferred_term: Secondary microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional neurologic features include hypotonia, microcephaly developing by age 12 months"
    explanation: >-
      GeneReviews lists postnatally-developing microcephaly as a neurologic
      feature.
- name: Axial Hypotonia
  description: >-
    Hypotonia, often axial, is a common neurologic feature.
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional neurologic features include hypotonia, microcephaly developing by age 12 months"
    explanation: >-
      GeneReviews lists hypotonia among the neurologic features.
- name: Autonomic Manifestations (Apnea, Cyanosis)
  description: >-
    Autonomic features such as perioral cyanosis, flushing, and apnea are common.
  phenotype_term:
    preferred_term: Apnea
    term:
      id: HP:0002104
      label: Apnea
  evidence:
  - reference: PMID:30234941
    reference_title: "KCNT1-Related Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autonomic manifestations (e.g., perioral cyanosis, flushing, apnea) are common"
    explanation: >-
      GeneReviews documents common autonomic manifestations including apnea and
      perioral cyanosis.
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: ULTRA_RARE
  notes: >-
    EIMFS is an ultra-rare developmental and epileptic encephalopathy; a precise
    population prevalence is not established. KCNT1 gain-of-function variants
    account for roughly 40-50% of cases.
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "To date, approximately 80 MMPSI patients have been reported with males and females being equally affected"
    explanation: >-
      A cumulative literature total of roughly 80 reported patients places the
      syndrome in the ultra-rare band. Graded INDIRECT because a case count is
      not a population prevalence measurement.
genetic:
- name: KCNT1
  gene_term:
    preferred_term: KCNT1
    term:
      id: hgnc:18865
      label: KCNT1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    KCNT1 encodes the sodium-activated potassium channel Slack (KNa1.1);
    gain-of-function variants are the most common cause of EIMFS. Most are de
    novo, and the same channel underlies other epilepsies (e.g., sleep-related
    hypermotor epilepsy).
  evidence:
  - reference: PMID:23086397
    reference_title: "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in total identifying mutations in 6 out of 12 unrelated affected individuals"
    explanation: >-
      KCNT1 mutations were found in half of an MMPSI cohort, establishing it as
      the major causative gene.
treatments:
- name: Quinidine (KCNT1 Blocker)
  description: >-
    Quinidine, a partial blocker of the Slack (KCNT1) channel, has been used as
    a precision therapy that targets the gain-of-function mechanism. In a
    systematic review of KCNT1-related epilepsy it benefited a subset of EIMFS
    patients (about 45%), with variable responses and required cardiac QT
    monitoring.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Increased Slack Sodium-Activated Potassium Current
    treatment_effect: INHIBITS
    description: >-
      Quinidine partially blocks the gain-of-function Slack potassium current.
    evidence:
    - reference: PMID:24591078
      reference_title: "KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "exposure to quinidine significantly reduces this gain of function for all mutations studied"
      explanation: >-
        Two-electrode voltage clamp of human KCNT1 variants, including the
        EIMFS-associated ones, shows quinidine reduces the gain of function,
        which is the mechanism this link asserts.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: quinidine
      term:
        id: CHEBI:28593
        label: quinidine
  evidence:
  - reference: PMID:39093319
    reference_title: "Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "QUIN resulted in benefit in 44.6% (25/56)"
    explanation: >-
      In a systematic review, quinidine benefited about 45% of EIMFS patients,
      supporting it as a partially effective precision therapy.
- name: Ketogenic Diet
  description: >-
    The ketogenic diet is a useful option in KCNT1-related epilepsy and, in a
    systematic review, benefited the largest fraction of EIMFS patients among
    the therapies compared.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:39093319
    reference_title: "Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KD resulted in benefit in 62.5% (25/40)"
    explanation: >-
      The ketogenic diet benefited 62.5% of EIMFS patients in the systematic
      review, the highest response among compared therapies.
- name: Cannabidiol
  description: >-
    Cannabidiol has been trialed in KCNT1-related epilepsy and benefited about
    half of the EIMFS patients in a systematic review.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cannabidiol
      term:
        id: CHEBI:69478
        label: cannabidiol
  evidence:
  - reference: PMID:39093319
    reference_title: "Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all types of CBD resulted in benefit in 50% (6/12)"
    explanation: >-
      In a systematic review, cannabidiol benefited 50% of EIMFS patients in
      whom it was tried.
- name: Antiseizure Medication
  description: >-
    Broad-spectrum antiseizure medications are used, but seizures are typically
    highly drug-resistant and conventional agents are only rarely beneficial.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:39093319
    reference_title: "Efficacy of anti-seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1-related epilepsy: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "conventional ASM are rarely reported as beneficial (in 5%-25% of patients)"
    explanation: >-
      Conventional antiseizure medications are only rarely beneficial in
      KCNT1-related epilepsy, underscoring the drug-resistance.
datasets:
- accession: geo:GSE297948
  title: Therapeutic Potential of ASO-Mediated KCNT1 Knockdown in KCNT1 Epileptic Encephalopathy
  description: KCNT1-related epileptic encephalopathy, including Epilepsy of Infancy with Migrating Focal Seizures (EIMFS), is a severe neurodevelopmental disorder associated with refractory seizures, profound neurologic impairment, and premature death. It is caused by de novo genetic variants in KCNT1 which alter the function of Slack, an evolutionarily conserved sodium-gated potassium channel that modulates neuronal firing patterns and excitability. Pathogenic KCNT1 variants lead to overactive Slack channels, boosting total neuronal potassium currents by up to 40%, driving cortical hyperexcitability and causing seizures.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 12
  publication: PMID:41981306
  notes: Identified by GEO DataSets index search for Epilepsy of Infancy with Migrating Focal Seizures (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
discussions:
- discussion_id: eimfs-gof-hyperexcitability-paradox
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction"
  - "pathophysiology#Increased Slack Sodium-Activated Potassium Current"
  prompt: >-
    KCNT1 variants in EIMFS increase a potassium current, which in isolation is
    hyperpolarizing and would be expected to reduce excitability - yet the result
    is severe, near-continuous seizures. By what circuit mechanism does a
    gain-of-function potassium channel produce network hyperexcitability, and how
    central is the proposed preferential effect on inhibitory interneurons?
  rationale: >-
    Resolving the gain-of-function paradox is essential for rational therapy: if
    the seizures arise chiefly from interneuron dysfunction, the therapeutic
    logic (and the interpretation of channel blockers) differs from a model in
    which principal-neuron firing is the driver. The interneuron hypothesis is
    plausible but not firmly established in human cortex.
  proposed_experiments:
  - experiment_id: eimfs-celltype-circuit
    name: Cell-type-resolved circuit study of KCNT1 gain of function
    description: >-
      Use cell-type-specific expression of EIMFS KCNT1 variants in
      excitatory versus inhibitory neurons (in iPSC-derived human neurons and
      animal models) with circuit-level recording to determine how the enhanced
      current translates into network hyperexcitability.
    readouts:
    - name: Effect of KCNT1 gain of function by neuron type on network excitability
      target: "pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction"
    would_support:
    - "pathophysiology#Disrupted Neuronal Firing and Interneuron Dysfunction"
- discussion_id: eimfs-quinidine-variable-response
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - "pathophysiology#Increased Slack Sodium-Activated Potassium Current"
  prompt: >-
    Quinidine blocks gain-of-function KCNT1 channels in vitro, motivating its use
    as a precision therapy, yet clinical benefit in EIMFS is inconsistent (around
    45% of patients). Why does the in vitro channel block translate so variably
    to seizure control - is it variant-specific pharmacology, CNS penetration,
    QT-limited dosing, or timing relative to established encephalopathy?
  rationale: >-
    The mismatch between reliable in vitro block and variable clinical response
    is the central obstacle to KCNT1 precision therapy. Evidence for target
    engagement exists in cell models, but its translational validity for seizure
    control in patients is uncertain, so predicting responders remains unsolved.
  proposed_experiments:
  - experiment_id: eimfs-quinidine-responder
    name: Variant-stratified quinidine response study
    description: >-
      Correlate quinidine clinical response with KCNT1 variant, in vitro block
      potency, achieved CSF/plasma levels, QT-limited dosing, and age at
      treatment across a multicenter EIMFS cohort to identify determinants of
      response.
    readouts:
    - name: Seizure response versus variant, drug level, and timing
      target: "pathophysiology#Migrating Focal Seizure Generation"
    decision_criterion: >-
      Identification of reproducible responder predictors would support
      variant-stratified quinidine use.
    would_support:
    - "pathophysiology#Increased Slack Sodium-Activated Potassium Current"
- discussion_id: eimfs-kcnt1-genotype-phenotype
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#KCNT1 Gain-of-Function Mutation"
  prompt: >-
    Gain-of-function KCNT1 variants cause a spectrum from severe EIMFS to the
    much milder autosomal dominant sleep-related hypermotor epilepsy. What
    determines whether the same channel defect produces devastating migrating
    seizures or a relatively mild focal epilepsy - variant location, degree of
    gain of function, mosaicism, or modifiers?
  rationale: >-
    Understanding what sets phenotypic severity from a shared gene would improve
    prognostic counseling and might reveal modifiable factors, but the
    genotype-phenotype relationship for KCNT1 is only partially mapped.
  proposed_experiments:
  - experiment_id: eimfs-kcnt1-genotype-severity
    name: KCNT1 genotype-severity mapping
    description: >-
      Relate the degree of channel gain of function (and variant location and
      mosaic fraction) to clinical severity across the KCNT1 phenotypic spectrum
      using functional assays and deep phenotyping.
    readouts:
    - name: Gain-of-function magnitude versus clinical severity
      target: "pathophysiology#KCNT1 Gain-of-Function Mutation"
    would_support:
    - "pathophysiology#KCNT1 Gain-of-Function Mutation"

📚

References & Deep Research

References

1

PMID:30234941

KCNT1-Related Epilepsy

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Epilepsy of Infancy with Migrating Focal Seizures · 2026-07-18T15:13:28Z · View source

De-novo curation of EIMFS (MONDO:0100025), a KCNT1 developmental and epileptic encephalopathy and pediatric-epilepsy gap entry. Granular unbundled pathophysiology: KCNT1 gain-of-function -> increased Slack (KNa) potassium current -> disrupted neuronal firing / interneuron dysfunction -> multifocal cortical hyperexcitability (conforms epilepsy module) -> migrating focal seizures (conforms) -> severe DEE. Evidence: Barcia 2012 (PMID:23086397, de novo GOF KCNT1, constitutive activation, 6/12 cohort) and a KCNT1 systematic review (PMID:39093319, quinidine 44.6%, ketogenic diet 62.5%, conventional ASM rarely beneficial). Treatments include quinidine (precision, target_mechanisms->Slack current), ketogenic diet, AEDs. Three discussions: GOF-hyperexcitability paradox (KNOWLEDGE_GAP), quinidine variable response (HUMAN_MODEL_MISMATCH), KCNT1 genotype-phenotype (KNOWLEDGE_GAP). claude_code deep research used as leads; NEC clean (KCNT1/MMPSI/MONDO:0100025). All snippets verified exact; schema + term validation pass.

Claude Code ▸

Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) — Disease Characteristics Research Report

claude-haiku-4-5-20251001, claude-opus-4-8 18 citations 2026-07-18T11:11:46.379563

Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) — Disease Characteristics Research Report

sup Harry — so this one's a real heartbreaker of a disease. EIMFS is one of the nastiest early-life epilepsies we know of: a baby's brain gets a channel stuck in the "on" position and seizures start wandering around the cortex like a storm system that never clears. Below is the full workup. One housekeeping note up top, because your whole repo is built around not trusting synthesized citations: the PMIDs I personally pulled and confirmed this session are 31872048, 29196579, 30234941, 36173683, and 32505479. Everything else I've named by author/journal/year and tagged [verify] — run just fetch-reference on those before any snippet lands in a YAML. Don't let me hand you a hallucinated quote.

1. Disease Information

What it is. EIMFS is a rare, severe developmental and epileptic encephalopathy (DEE) of early infancy. The defining feature is migrating focal seizures — focal (partial) seizures that arise independently at multiple, shifting cortical foci and appear to "travel" from one brain region or hemisphere to another, both within a single seizure and across seizures. They're relentlessly drug-resistant, become nearly continuous by 6–9 months of age, and drag psychomotor development to a halt (arrest, then regression). Think of it less like a single short-circuit and more like a grid where breakers keep tripping in a rolling blackout across the whole city.

Key identifiers: | Resource | ID | |---|---| | OMIM | 614959 — Developmental and epileptic encephalopathy 14 (DEE14; formerly EIEE14), the KCNT1 locus | | Orphanet | ORPHA:293181 | | MONDO | ~MONDO:0013820 [verify against sqlite:obo:mondo — run the NEC preflight, this is a numbered-DEE series and prime named-entity-confusion territory] | | ICD-11 | 8A62 (Developmental and epileptic encephalopathies) — no leaf code specific to EIMFS | | ICD-10 | G40.4 (other generalized epilepsy) is the usual crosswalk; no specific code | | MeSH | No dedicated descriptor; indexed under Epilepsies, Partial / Spasms, Infantile / Epileptic Encephalopathy |

Synonyms / alternative names: Malignant Migrating Partial Seizures of Infancy (MMPSI — the original 1995 name, Coppola et al.), Migrating Partial Seizures of Infancy (MPSI), Migrating Partial Epilepsy of Infancy, and gene-anchored labels like KCNT1-related epilepsy / DEE14. ILAE now formally recognizes EIMFS as a distinct infantile-onset epilepsy syndrome in its 2022 neonatal/infantile classification.

Data provenance. This report is built from aggregated disease-level resources (OMIM, Orphanet, GeneReviews, ILAE classification) plus cohort and case-series primary literature — not individual EHR data.

Sources: GeneReviews KCNT1-Related Epilepsy (PMID:30234941); MedlinePlus EIMFS; ILAE 2022 syndrome classification.

2. Etiology

Primary cause: genetic. EIMFS is genetically heterogeneous, but one gene dominates: KCNT1, where de novo gain-of-function missense variants account for roughly ~40–50% of cases. This is the flagship story — Barcia et al. (Nature Genetics 2012, [verify PMID:23086397]) first tied KCNT1 gain-of-function to MMPSI.

Genetic risk factors / causal variants. Beyond KCNT1, a long tail of genes has been reported. The consistently replicated second-tier causes: - SCN2A — second most common genetic cause of EIMFS - SCN1A, SCN8A — voltage-gated sodium channels - SLC25A22 — mitochondrial glutamate carrier (autosomal recessive) - TBC1D24 — recessive - PLCB1 — phospholipase C beta 1 (recessive) - SLC12A5 (KCC2) — biallelic loss-of-function impairing the neuronal chloride exporter (Stödberg et al. Nat Commun 2015 [verify PMID:26333769]; Saitsu et al. 2016) - KCNT2 — de novo variants exerting inhibitory effects on the heteromeric KNa1.1/KNa1.2 channel (Ambrosino et al., Front Mol Neurosci — PMC6992647 [verify PMID])

A broader list reported in EIMFS/EIMFS-like presentations includes KCNQ2, CDKL5, GABRB3/GABRA1/GABRG2, HCN1, ITPA, QARS, FARS2, KARS, BRAT1, ATP1A3, WWOX, PCDH19, SMC1A, PIGA and others — many of these are "EIMFS-like" rather than classic.

Environmental / non-genetic factors. EIMFS is fundamentally a monogenic channelopathy — there is no established environmental, infectious, or toxic cause, and no meaningful lifestyle or occupational exposure signal (it's an infant disease). Age (first months of life) and the presence of a pathogenic variant are the whole story.

Protective factors. None described genetically or environmentally. This isn't a complex-trait disease with modifiable risk — it's a single dominant-acting molecular lesion. [Not applicable / not available.]

Gene–environment interactions. Not applicable in the usual GxE sense. The one "interaction" worth curating is modifier/second-hit variability: the same KCNT1 variant can produce anything from lethal EIMFS to an asymptomatic carrier within one family (see §4, §9), which points to genetic-background modifiers we haven't mapped yet.

Sources: KCNT1 hotspots paper (PMID:31872048); Genetic Landscape of EIMFS; Locus Heterogeneity in EIMFS.

3. Phenotypes

Onset is neonatal-to-early-infantile — mean seizure onset ~1 month (range: 1 hour of life to ~4 months, occasionally up to ~7 months) per the 17-patient cohort in PMID:31872048. Course is progressive: milestones may be reached briefly, then arrest and regression follow seizure onset.

Phenotype	Type	Characteristics	Suggested HPO
Migrating focal (multifocal) seizures	Clinical/electrographic sign	The defining feature; onset <6 mo; near-continuous by 6–9 mo; pharmacoresistant	HP:0011153 Focal-onset seizure; HP:0032807 Migrating focal seizures
Focal motor seizures	Symptom	Clonic/tonic limb, eye deviation, head turning	HP:0011153
Autonomic features (apnea, perioral cyanosis, flushing, apnea/desaturation, salivation)	Sign	"Common"; can be the presenting event	HP:0011153 + HP:0002104 Apnea; HP:0000961 Cyanosis
Seizure intractability / drug resistance	Sign	Refractory to multiple ASMs	HP:0032794 Refractory epilepsy
Developmental arrest / regression	Sign	Onset after seizures begin; near-universal	HP:0002376 Developmental regression
Profound intellectual disability / global developmental delay	Sign	Most never walk or speak	HP:0002187 Profound global developmental delay; HP:0010864 Intellectual disability, severe
Acquired microcephaly	Physical	Postnatal deceleration of head growth	HP:0005484 Postnatal microcephaly
Axial hypotonia	Sign	Common; with later appendicular spasticity/dystonia	HP:0008936 Axial hypotonia
Dystonia / movement disorder (incl. status dystonicus)	Sign	Reported with specific KCNT1 variants	HP:0001332 Dystonia
Choreoathetosis / abnormal movements	Sign		HP:0001269
Feeding difficulties / failure to thrive	Sign	Secondary; frequently needs G-tube	HP:0011968 Feeding difficulties
Peripheral autonomic dysregulation (temperature instability, GI dysmotility)	Sign		HP:0002027 Abdominal pain / HP:0012332 Abnormal autonomic nervous system physiology
Cortical visual impairment	Sign		HP:0100704 Cerebral visual impairment
Rare: pulmonary hemorrhage (ages 4–19 mo)	Lab/clinical	KCNT1-specific, potentially fatal	HP:0002105 Hemoptysis
Rare: cardiac arrhythmia / Brugada pattern	Lab/clinical	KCNT1 is expressed in heart; relevant for quinidine safety	HP:0011675 Arrhythmia

EEG signature (the electrophysiology is diagnostic): migrating ictal pattern — ictal discharges begin focally, then involve progressively adjacent and contralateral regions with independent multifocal onsets. Interictal backgrounds are abnormal; suppression-burst (4/17) and hypsarrhythmia with infantile spasms (3/17) were seen in the hotspots cohort (PMID:31872048).

Frequency among affected: migrating seizures, refractoriness, developmental arrest → essentially universal (definitional). Autonomic features "common." Movement disorders and the rare pulmonary/cardiac features are variant-associated minorities.

Quality of life: Catastrophic. Profound disability means near-total dependence for feeding, mobility, and communication; families bear enormous caregiving burden. No EIMFS-specific validated QoL instrument exists — generic pediatric DEE tools (e.g., caregiver-reported measures) are what's used. [Per-phenotype QoL data: not available.]

Sources: KCNT1 hotspots (PMID:31872048); GeneReviews (PMID:30234941); 36-patient cohort, Sci Rep 2022.

4. Genetic / Molecular Information

Causal gene — KCNT1 (HGNC:18865; hgnc:18865; OMIM 608167; chr 9q34.3). Encodes KNa1.1 (a.k.a. Slack, SLO2.2), a sodium-activated potassium channel — a large-conductance K⁺ channel gated by intracellular Na⁺ (and Cl⁻), assembling as a tetramer with a big cytoplasmic C-terminal RCK (regulator of K⁺ conductance) domain. It sets the slow after-hyperpolarization and tunes neuronal firing.

Variant class: Nearly all pathogenic KCNT1 variants are heterozygous missense (loss-of-function/truncating is rare and tends to give milder or different phenotypes). Functional consequence = gain of function: mutant channels show markedly increased K⁺ current amplitude, and multiple variants cause constitutive opening / loss of cooperative gating. There's growing evidence for a second mechanism — impaired non-conducting functions, i.e., the mutant C-terminus fails to properly interact with developmental signaling partners like FMRP (fragile-X mental retardation protein) — so it's not purely "too much potassium current."

Mutation hotspots (recurrent residues, mostly C-terminal): p.G288S (pore region), p.R398Q, p.R428Q, p.R474C, p.R474H, p.A934T, plus p.L437P, p.M516V, p.M896I, p.A965V, p.R1106P and others (PMID:31872048). Computational modeling implicates abnormal pore function and impaired tetramer assembly.

Genotype–phenotype (weak, but a trend): EIMFS-associated variants cluster in the S5 transmembrane and RCK/NAD⁺-binding (C-terminal) domains; ADNFLE variants concentrate near the NAD⁺-binding domain. BUT — and this is the load-bearing caveat — the same variant (p.G288S, p.R398Q, p.A934T) shows up in both EIMFS and ADNFLE, sometimes within one family (the R398Q three-generation family: severe EIMFS proband, ADNFLE father, asymptomatic uncle). So no clean single-variant → single-phenotype rule exists. Modifier genes are strongly implicated but unmapped.

Allele frequency: Pathogenic KCNT1 EIMFS variants are de novo and essentially absent from gnomAD (as expected for a lethal-tending dominant DEE). ADNFLE variants may recur in families.

Somatic vs germline: Predominantly germline de novo. But somatic and germline mosaicism have been documented — in unaffected/mildly affected transmitting parents, and low-level somatic mosaicism can modulate severity. Relevant for recurrence counseling.

Modifier genes / epigenetics / chromosomal abnormalities: Modifiers strongly suspected (intrafamilial variability) but not characterized. No epigenetic mechanism and no chromosomal/structural abnormality is part of the EIMFS mechanism — this is a point-mutation channelopathy. [Not applicable for CNV/karyotype.]

Suggested GO / entities: GO:0005228 intracellular sodium activated potassium channel activity; GO:0008076 voltage-gated potassium channel complex; GO:0051260 protein homooligomerization (tetramer assembly); CHEBI:29103 potassium(1+); CHEBI:29101 sodium(1+).

Sources: KCNT1 hotspots (PMID:31872048); KCNT1-related severe early-onset epilepsy (PMID:29196579); GeneReviews (PMID:30234941); status dystonicus KCNT1 variant.

5. Environmental Information

There is essentially nothing to curate here, and that's itself the finding. EIMFS is a monogenic developmental channelopathy with no established environmental, lifestyle, or infectious contribution. It's a congenital/early-infantile genetic disease — no toxin, radiation, pollutant, occupational exposure, diet, or pathogen has been shown to cause or trigger it. Fever and intercurrent illness can provoke seizure worsening (as in any epilepsy), but that's a nonspecific seizure threshold effect, not an etiologic factor. [Environmental / infectious factors: not applicable.]

6. Mechanism / Pathophysiology

The causal chain (upstream → downstream):

De novo GoF missense variant in KCNT1 →
Constitutively hyperactive KNa1.1 (Slack) channels — increased Na⁺-activated K⁺ current, loss of cooperative gating, channels open when they shouldn't →
Paradoxically, this K⁺ hyperactivity in specific neuronal populations (notably GABAergic interneurons) is thought to shorten action potentials / speed repolarization and dampen inhibitory interneuron output, tipping the network toward excitation–inhibition imbalance →
Neuronal hyperexcitability and hypersynchrony across multiple independent cortical foci →
Migrating multifocal seizures + epileptogenesis →
Ongoing seizures + disrupted KCNT1 developmental signaling → developmental arrest / regression / encephalopathy.

This is a clean conformer to your epilepsy_excitation_inhibition_imbalance module — the key target node epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance maps directly onto steps 3–4. And there's a nice mechanistic twist worth a mechanistic_hypotheses block: EIMFS is a rare case where a gain-of-function in a potassium (inhibitory-current) channel causes hyperexcitability — the resolution is cell-type-specific (the interneuron story), which is a genuinely open question and a good candidate for a HUMAN_MODEL_MISMATCH or KNOWLEDGE_GAP discussion.

Second mechanistic arm — non-conducting functions: KCNT1's C-terminus scaffolds developmental signaling proteins (FMRP among them). Mutations disrupt these protein–protein interactions independent of ion flux, which may explain why the encephalopathy is more severe than pure ictal burden predicts, and flags a therapeutic target beyond channel-blockade.

Molecular pathways / cellular processes: Ion transport / membrane potential regulation (GO:0006813 potassium ion transport; GO:0051899 membrane depolarization; GO:0019228 neuronal action potential); synaptic transmission, GABAergic (GO:0051932); regulation of neuronal excitability.
Protein dysfunction: Gain-of-function channel opening + impaired oligomerization/tetramer formation + disrupted C-terminal interactome. Not misfolding/aggregation — it's a hyperfunctional, mis-gated channel.
Cell types (CL): cortical GABAergic interneuron (CL:0000617), glutamatergic/pyramidal neuron (CL:0000598 / CL:0000679). KCNT1 is broadly expressed in CNS neurons.
Immune / metabolic / fibrosis / oxidative-stress mechanisms: Not involved. (Exception: the SLC25A22 recessive form is a mitochondrial glutamate-transport/energetics defect — but that's a distinct EIMFS-causing gene, not the KCNT1 mechanism.)
Molecular profiling (transcriptomics/proteomics/metabolomics): No robust human EIMFS omics signature published. Mechanistic data come from heterologous electrophysiology (Xenopus oocyte / mammalian cell expression, patch-clamp) and mouse models, not patient tissue omics. [Omics: largely not available.]
Functional genomics: Rescue/knockdown work exists via ASO in mouse (see §12), not CRISPR screens.

Sources: KCNT1-related severe early-onset epilepsy (PMID:29196579); Neurology Genetics migrating focal seizures; KCNT1 hotspots (PMID:31872048).

7. Anatomical Structures Affected

Organ level (primary): Brain — the cerebral cortex (UBERON:0000956), diffusely and multifocally; this is a whole-cortex network disease, not a single-lobe focus. Nervous system (UBERON:0001016) is the affected body system.
Secondary organ involvement: Systemic sequelae of severe DEE — respiratory (aspiration, apnea; rare pulmonary hemorrhage), cardiac (KCNT1 arrhythmia / Brugada risk — genuinely important because quinidine has cardiac effects), GI (dysmotility, feeding failure). Growth (postnatal microcephaly).
Neuroimaging structural correlates: Brain MRI is often normal early, but longitudinal imaging shows delayed myelination, progressive cerebral/cerebellar atrophy, and hippocampal volume loss — i.e., acquired, not malformative. (Cerebellum UBERON:0002037; hippocampus UBERON:0002421.)
Tissue / cell level: Nervous tissue; cortical GABAergic interneurons (CL:0000617) and glutamatergic pyramidal neurons (CL:0000679) are the mechanistically central populations.
Subcellular (GO Cellular Component): plasma membrane (GO:0005886), voltage-gated potassium channel complex (GO:0008076), neuronal cell body / axon initial segment where Slack channels localize.
Localization / lateralization: Bilateral, asymmetric, multifocal, shifting — the "migrating"/independent-multifocal onset is the anatomic hallmark. No fixed lateralization.

8. Temporal Development

Onset: Neonatal to early infantile. Mean ~1 month; range from the first hours/week of life to ~4 (occasionally ~7) months. Onset pattern is subacute-to-progressive — seizures start, then escalate.
Progression / stages:
Early phase — focal seizures begin, initially sporadic, sometimes with brief normal or near-normal development.
Peak/plateau phase (~6–9 months) — seizures become very frequent to near-continuous, migrating multifocal pattern fully established; developmental arrest then regression.
Chronic phase — seizure frequency may fluctuate/partially wane in some survivors over years, but profound disability persists; spasticity/dystonia and microcephaly evolve.
Progression rate: Rapid in the first year; then chronic-static-to-slowly-progressive disability.
Course pattern: Chronic, lifelong, pharmacoresistant; seizures episodic-to-continuous.
Remission: Spontaneous remission is rare. Rare partial, treatment-associated responses reported (quinidine in some KCNT1 cases; ketogenic diet occasionally) but true seizure freedom is uncommon and developmental outcome rarely normalizes even when seizures improve.
Critical window: The first months of life are both the vulnerability window and the presumed therapeutic window — the whole rationale behind early quinidine and future genetic therapies is intervening before irreversible developmental injury accrues.

Sources: GeneReviews (PMID:30234941); 36-patient cohort.

9. Inheritance and Population

Epidemiology. EIMFS is rare/ultra-rare — an estimated prevalence on the order of ~0.11 per 100,000 children (i.e., roughly 1 in ~900,000; well within Orphanet's ultra-rare band). Incidence figures are not firmly established; it's a small slice of the overall DEE burden (cumulative DEE incidence ~169/100,000). Literature has aggregated on the order of ~120 patients across ~116 families for KCNT1 specifically as of the hotspots review (PMID:31872048), with GeneReviews citing ~88 KCNT1 probands.

Prevalence class (for the KB): BELOW_1_IN_1000000–ULTRA_RARE neighborhood; rate_per_100000 ≈ 0.11, measure_type: POINT_PREVALENCE.

Inheritance pattern: - KCNT1 EIMFS = de novo, autosomal dominant — essentially all EIMFS probands are simplex cases from a de novo variant (HP:0000006 Autosomal dominant inheritance; often effectively sporadic). - Recessive forms exist for other genes: SLC25A22, TBC1D24, PLCB1, SLC12A5 are autosomal recessive (HP:0000007) — consanguinity is relevant for those. - Penetrance: ~100% for KCNT1-related EIMFS; reduced/variable for the milder KCNT1 phenotypes (ADNFLE, asymptomatic carriers). - Expressivity: Highly variable — the same variant spans lethal EIMFS to asymptomatic within a single pedigree. - Genetic anticipation: Not a feature (not a repeat-expansion disorder). [Not applicable.] - Mosaicism: Documented — somatic and germline mosaicism in transmitting parents; matters for recurrence-risk counseling. - Founder effects / carrier frequency: No founder effect described; de novo variants aren't in population carrier databases. [Not applicable.]

Population demographics: - Ethnicity/geography: No ethnic predilection; reported worldwide (European, North American, East Asian, South Indian cohorts all published). No endemic geography. - Sex ratio: Roughly equal / no strong sex bias (the 17-patient cohort was 8 F / 9 M). - Age distribution: By definition an infantile-onset disorder; the affected population is children (and the reduced number of survivors reaching later childhood/adulthood with profound disability).

Sources: KCNT1 hotspots (PMID:31872048); GeneReviews (PMID:30234941); DEE epidemiology.

10. Diagnostics

The diagnostic pillars are EEG + genetics.

Electrophysiology (central): Video-EEG showing the migrating ictal pattern — focal ictal discharges arising independently at multiple sites, migrating across contiguous regions and between hemispheres, on an abnormal interictal background (± suppression-burst, ± hypsarrhythmia). This is the phenotypic anchor of the diagnosis. ECG/Holter is important adjunctively — both to screen for KCNT1-associated arrhythmia and as baseline before quinidine.
Imaging: Brain MRI — typically normal early; used to exclude structural/malformative and metabolic mimics, and to track later atrophy/myelination delay.
Laboratory / metabolic workup: Done to exclude treatable metabolic epilepsies (e.g., pyridoxine-dependent/ALDH7A1, PNPO, glucose transporter, mitochondrial disorders) — CSF/serum metabolic panels, lactate, amino/organic acids. Normal in KCNT1 EIMFS; abnormal points you to a different diagnosis.
Genetic testing (definitive):
First-line: broad epilepsy/DEE next-generation-sequencing panel or exome/genome (WES/WGS) — GeneReviews explicitly recommends multigene panel or comprehensive genomic testing over single-gene testing given locus heterogeneity. Sequence analysis detects ~100% of KCNT1 variants.
Single-gene KCNT1 testing only when the EEG/clinical picture is classic and you want targeted confirmation.
CMA / karyotype / FISH: low yield (this is a point-mutation disease) but part of a general DEE workup to exclude CNV mimics. [Mostly not applicable.]
Repeat-expansion / mtDNA testing: not indicated for KCNT1; mtDNA relevant only if a mitochondrial phenotype (e.g., SLC25A22-like) is suspected.
Omics-based diagnostics: No validated clinical omics assay for EIMFS beyond DNA sequencing. [RNA-seq/proteomics/metabolomics: research-only / not available.]
Clinical/diagnostic criteria: ILAE 2022 infantile-onset syndrome criteria for EIMFS (characteristic seizure semiology + migrating EEG pattern + developmental course), plus molecular confirmation.
Differential diagnosis: other early-infantile DEEs — Ohtahara syndrome / early-infantile DEE, West syndrome (infantile spasms), Dravet syndrome (SCN1A), KCNQ2 encephalopathy, CDKL5 deficiency, pyridoxine/PNPO-responsive epilepsies, GLUT1 deficiency, and structural/metabolic epilepsies. Distinguishing feature: the migrating multifocal ictal EEG pattern + KCNT1 genotype.
Screening: No population newborn screen. Cascade testing in families is complicated by mosaicism/variable expressivity; genetic counseling is essential.

Sources: GeneReviews (PMID:30234941); MedLink EIMFS.

11. Outcome / Prognosis

Prognosis is poor — this is one of the most severe DEEs. In the well-characterized 36-patient EIMFS cohort (Sci Rep 2022): 13/36 had ineffective seizure control, 14/36 had severe intellectual disability, and 6/36 died. GeneReviews frames long-term EIMFS prognosis as still incompletely defined but uniformly severe.

Survival / mortality: Reduced life expectancy. Early mortality is substantial (roughly ~15–20% in cohorts), from status epilepticus, intercurrent illness/aspiration, the rare pulmonary hemorrhage, and SUDEP (sudden unexpected death in epilepsy) risk inherent to severe drug-resistant epilepsy. Formal 5-/10-year survival curves aren't well established given rarity.
Morbidity / function: Profound, lifelong. Most survivors have severe-to-profound intellectual disability, never achieve independent ambulation or speech, and depend fully on caregivers; spasticity, dystonia, microcephaly, feeding difficulty (frequent G-tube), and cortical visual impairment are common.
Disease course / complications: recurrent status epilepticus, aspiration pneumonia, growth failure, orthopedic complications of spasticity, and the KCNT1-specific rare complications (pulmonary hemorrhage, cardiac arrhythmia).
Recovery potential: Low. Even when seizures partially respond (e.g., quinidine responders), developmental outcome rarely normalizes — quinidine cut seizure burden ~90% in two reported responders but did not rescue developmental milestones.
Prognostic factors: earlier onset and higher seizure burden trend worse; specific variant and (hypothesized) modifier background influence severity; early effective seizure control is the main potentially modifiable factor and the rationale for early targeted therapy.
Prognostic biomarkers: none validated beyond genotype and seizure-control trajectory. [Molecular prognostic markers: not available.]

QoL measures: generic pediatric/caregiver DEE instruments; no EIMFS-specific validated tool.

Sources: 36-patient cohort; GeneReviews (PMID:30234941); early quinidine 2-patient study.

12. Treatment

The honest headline: it's mostly refractory, and the "precision" drug (quinidine) has been a genuine disappointment outside a few responders. The real hope is upstream — genetic therapy.

Pharmacotherapy — conventional antiseizure medicines (ASMs): - Broadly drug-resistant. Combinations tried include stiripentol + benzodiazepines (clonazepam), levetiracetam, sodium-channel blockers, topiramate, vigabatrin, etc. Responses are partial at best. - MAXO/NCIT: NCIT:C15986 Pharmacotherapy; MAXO:0000009 pharmacotherapy.

Targeted / precision therapy — Quinidine (the marquee "channelopathy repurposing" story): - Rationale: Quinidine is a partial KNa1.1/Slack blocker → it should counteract KCNT1 gain-of-function. Milligan et al. (2014) showed quinidine reverses KCNT1 GoF in vitro [verify PMID:24838348]; Bearden et al. (2014) first reported clinical benefit in a patient [verify]. - Reality check: Results are highly variable and often disappointing. Some KCNT1-EIMFS patients (esp. with early treatment + drug-level/cardiac monitoring) get ~90% seizure reduction (2-patient study); many others get no benefit and dose-limiting cardiotoxicity (QT prolongation, arrhythmia). A randomized quinidine trial in KCNT1-ADNFLE was negative (Mullen et al. 2018 [verify PMID:~29196578]). GeneReviews is notably cautious. Bottom line for the KB: quinidine is a variant-/patient-dependent option requiring cardiac monitoring and therapeutic drug level titration — not a reliable cure. Variable in-vitro blockade across variants partly explains the inconsistency. - CHEBI: quinidine CHEBI:28593. Therapeutic_agent pattern fits here. - therapeutic_modality: SMALL_MOLECULE, with a target_mechanisms link back to the excitation–inhibition/KCNT1 node (INHIBITS).

Other pharmacological options: - Cannabidiol — used in refractory DEEs including some KCNT1 cases; anecdotal/limited EIMFS-specific evidence. CHEBI:69478. [Evidence limited.] - Nonnarcotic antitussives (cloperastine) — one notable case report of KCNT1-EIMFS seizure control after quinidine failure (PMID:32505479); mechanism putatively also Slack-related. Interesting lead, single case.

Dietary: - Ketogenic diet — tried; occasional partial responders; part of the standard refractory-DEE toolkit. MAXO:0000088 dietary intervention / ketogenic diet.

Advanced / experimental — the actual frontier: - Antisense oligonucleotide (ASO) therapy — the most exciting preclinical development. Burbano et al. (JCI Insight 2022, PMID:36173683) built a Kcnt1 p.P924L knock-in mouse; a single ICV bolus of a Kcnt1 gapmer ASO in symptomatic mice reduced seizure frequency, improved behavior, and extended survival in a gene-specific, dose-dependent way. This is a direct EIMFS gene-silencing precision therapy in the pipeline. Maps beautifully onto your antisense_oligonucleotide_therapy#Pathogenic mRNA Accumulation module node (RNase-H knockdown paradigm). therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE; aso_mechanism: RNASE_H_KNOCKDOWN; target_gene: KCNT1 (hgnc:18865). - A related cross-syndrome finding: reducing Kcnt1 was therapeutic in SCN1A and SCN8A epilepsy mouse models (Front Neurosci 2023) — suggesting Slack knockdown could be broadly useful. - No approved gene therapy / CRISPR / cell therapy yet; these remain preclinical.

Surgical / interventional: Resective epilepsy surgery is generally not applicable — the multifocal, migrating, bilateral nature means there's no single resectable focus. Vagus nerve stimulation (VNS) and corpus callosotomy have been tried as palliative options in refractory DEE with limited benefit.

Supportive / rehabilitative (the backbone of real-world care): seizure-rescue protocols, respiratory and feeding support (G-tube), physical/occupational/speech therapy, spasticity and dystonia management, and family/palliative support. MAXO:0000950 supportive care; MAXO:0000011 physical therapy.

Treatment strategy / algorithm: confirm genotype → trial standard ASMs → if KCNT1 GoF, consider early monitored quinidine (with cardiology) → ketogenic diet / cannabidiol as adjuncts → supportive/palliative care throughout → enroll in trials / watch the ASO pipeline. Genotype-guided care is the emerging paradigm.

Sources: ASO therapy for KCNT1 encephalopathy (PMID:36173683); early quinidine 2-patient study; cloperastine case report (PMID:32505479); Kcnt1 reduction in SCN1A/SCN8A models; GeneReviews (PMID:30234941).

13. Prevention

Because EIMFS is a de novo genetic disease with no environmental input, classic prevention doesn't apply — you can't lifestyle your way out of a de novo channel mutation. Prevention is essentially reproductive-genetic and tertiary.

Primary prevention: Not applicable in the public-health sense (no modifiable exposure, no vaccine, and de novo variants mean unaffected parents have no warning). The only "primary prevention" lever is reproductive: for families with a proven transmitting variant or germline mosaicism, preimplantation genetic testing (PGT-M) and prenatal diagnosis can prevent recurrence.
Secondary prevention (early detection): Rapid genetic diagnosis in a neonate/infant with the characteristic seizures + migrating EEG — the "screening" that matters is fast exome/genome sequencing to enable early genotype-guided treatment during the presumed therapeutic window. No population newborn screen exists.
Tertiary prevention (preventing complications): the mainstay — aggressive seizure/status-epilepticus management, aspiration/respiratory precautions, nutrition support, spasticity management, SUDEP-risk mitigation, and coordinated multidisciplinary care.
Genetic counseling: Essential. Covers the de novo/simplex nature, recurrence risk elevated by possible parental germline mosaicism (so recurrence risk isn't zero even with unaffected parents), and reproductive options. MAXO:0000079 genetic counseling.
Immunization / infectious / environmental interventions: Not applicable.

Sources: GeneReviews (PMID:30234941).

14. Other Species / Natural Disease

Taxonomy: Human disease — NCBITaxon:9606 (Homo sapiens). No naturally occurring animal counterpart is a recognized clinical entity.
Orthologous gene: Kcnt1 in mouse (Mus musculus, NCBITaxon:10090; NCBI Gene ID 227632) and rat; the Slack/KNa1.1 channel is evolutionarily conserved across vertebrates (and has an invertebrate homolog — Drosophila slowpoke-related slo-2).
Natural disease in other species: Not described — no spontaneous KCNT1-EIMFS reported in companion animals or wildlife (OMIA has no established equivalent). [Not available.]
Comparative biology: The conserved Slack channel makes engineered models highly translatable (see §15), but natural-disease comparative pathology data don't exist for EIMFS.
Transmission / zoonosis: Not applicable — genetic, non-communicable.

15. Model Organisms

Primary model — mouse (Mus musculus, MGI):
Kcnt1 p.P924L knock-in (Burbano et al., PMID:36173683): homozygotes recapitulate frequent debilitating seizures and developmental compromise; the platform used to validate ASO therapy. Model type: mammalian genetic knock-in (patient-variant humanized-equivalent).
Kcnt1 knockout and additional gain-of-function knock-in lines exist for mechanism and drug testing; Kcnt1 reduction was therapeutic in Scn1a and Scn8a epilepsy mouse models (Front Neurosci 2023).
In vitro / cellular models: Heterologous expression electrophysiology — Xenopus oocytes and mammalian cell lines (CHO/HEK) expressing mutant KCNT1 with patch-clamp — the workhorse for demonstrating gain-of-function, tetramer/pore modeling, and quinidine blockade sensitivity per variant. iPSC-derived neurons from patients are an emerging platform.
Model characteristics:
Phenotype recapitulation: good for the electrophysiologic gain-of-function and (in the knock-in) seizures + developmental phenotype; strong translational value for target validation and ASO/drug testing.
Limitations: human cell-type-specific interneuron circuitry, the non-conducting FMRP-interactome biology, and the full developmental-encephalopathy phenotype are incompletely captured; zygosity mismatch (mouse needs homozygous P924L vs. human heterozygous de novo) is a notable caveat — a good HUMAN_MODEL_MISMATCH flag for the KB.
Applications: dissecting GoF mechanism, testing channel blockers (quinidine and analogs), and preclinical validation of ASO gene-silencing — the main path to a real therapy.
Resources: MGI (Mouse Genome Informatics), IMPC/KOMP for Kcnt1 alleles, Cellosaurus for expression lines.

Sources: ASO therapy / Kcnt1 P924L mouse (PMID:36173683); Kcnt1 reduction in SCN1A/SCN8A models.

Curation quick-reference (for the dismech entry)

Module conformance: epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance (core), and antisense_oligonucleotide_therapy#Pathogenic mRNA Accumulation (KCNT1 ASO, RNase-H knockdown, target_gene: hgnc:18865).
Inheritance block: de novo AD (HP:0000006) for KCNT1; AR (HP:0000007) for SLC25A22/TBC1D24/PLCB1/SLC12A5 subforms — worth a has_subtypes split by gene.
Prevalence record: POINT_PREVALENCE, rate_per_100000 ≈ 0.11, ultra-rare band.
Genetic heterogeneity: consider case_fractions — KCNT1 ~40–50%, SCN2A second, long recessive/other-gene tail.
NEC preflight before you commit the MONDO ID — DEE14 sits in a numbered series (high named-entity-confusion risk); confirm the gene named in the MONDO def: is KCNT1 and the OMIM xref is 614959 before trusting MONDO:0013820.

Verified-this-session PMIDs (safe to fetch): 30234941 (GeneReviews), 31872048 (hotspots), 29196579 (KCNT1 severe early-onset characterization), 36173683 (ASO/JCI Insight), 32505479 (cloperastine case report).

PMIDs I named but did NOT verify this session — just fetch-reference and check the snippet before use: Barcia 2012 Nat Genet (KCNT1 GoF causes MMPSI), Milligan 2014 (quinidine reverses GoF in vitro), Bearden 2014 (first quinidine clinical use), Mullen 2018 (negative quinidine ADNFLE RCT), Stödberg/Saitsu 2015–2016 (SLC12A5), Coppola 1995 (original MMPSI description), and the KCNT2 EIMFS paper. Treat every one of those as a lead, not gospel — exactly the way your CLAUDE.md wants it.

Epilepsy of Infancy with Migrating Focal Seizures

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Prevalence

Related Datasets

Source YAML

References & Deep Research

References

Deep Research

Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) — Disease Characteristics Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Curation quick-reference (for the dismech entry)